TY - JOUR
T1 - Posttherapy surveillance of women with cervical cancer
T2 - An outcomes analysis
AU - Bodurka-Bevers, Diane
AU - Morris, Mitchell
AU - Eifel, Patricia J.
AU - Levenback, Charles
AU - Bevers, Michael W.
AU - Lucas, Kristin R.
AU - Wharton, J. Taylor
PY - 2000
Y1 - 2000
N2 - Objective. The aim of this study was to develop a surveillance program that optimizes clinical outcome following primary treatment of women with cervical cancer. Methods. The records of 1096 patients with FIGO stage IB cervical cancer treated from 1983 to 1993 were retrospectively reviewed. Recurrence was analyzed by site, presence or absence of symptoms, method of detection, and survival. Univariate and multivariate analyses using a Cox proportional hazards model were performed. Results. One hundred thirty-three patients (13%) developed recurrent disease. Of these, 114 were symptomatic and 19 were asymptomatic at the time of recurrence. Thirty-seven patients recurred in the central pelvis, 21 each in the lung or pelvic wall, 22 in nodes, and 35 in other sites. The median disease-free interval was 17 months for symptomatic patients and 16 months for asymptomatic patients. The median survival from initial diagnosis was 31 months for symptomatic and 83 months for asymptomatic patients (P = 0.001). The median survival from recurrence was 11 months for symptomatic and 42 months for asymptomatic patients (P < 0.001). Multivariate analysis revealed that symptom status at time of recurrence was a significant predictor of survival, even when known prognostic factors were considered (P < 0.001). All asymptomatic pelvic recurrences were diagnosed by pelvic exam; all asymptomatic pulmonary recurrences were detected by chest radiographs. Pap smears did not detect a single asymptomatic recurrence. Conclusions. Posttherapy surveillance programs are directed toward asymptomatic patients in whom early detection of recurrence may impact survival. These data indicate that a subset of women may benefit from surveillance. A model for surveillance is proposed. (C) 2000 Academic Press.
AB - Objective. The aim of this study was to develop a surveillance program that optimizes clinical outcome following primary treatment of women with cervical cancer. Methods. The records of 1096 patients with FIGO stage IB cervical cancer treated from 1983 to 1993 were retrospectively reviewed. Recurrence was analyzed by site, presence or absence of symptoms, method of detection, and survival. Univariate and multivariate analyses using a Cox proportional hazards model were performed. Results. One hundred thirty-three patients (13%) developed recurrent disease. Of these, 114 were symptomatic and 19 were asymptomatic at the time of recurrence. Thirty-seven patients recurred in the central pelvis, 21 each in the lung or pelvic wall, 22 in nodes, and 35 in other sites. The median disease-free interval was 17 months for symptomatic patients and 16 months for asymptomatic patients. The median survival from initial diagnosis was 31 months for symptomatic and 83 months for asymptomatic patients (P = 0.001). The median survival from recurrence was 11 months for symptomatic and 42 months for asymptomatic patients (P < 0.001). Multivariate analysis revealed that symptom status at time of recurrence was a significant predictor of survival, even when known prognostic factors were considered (P < 0.001). All asymptomatic pelvic recurrences were diagnosed by pelvic exam; all asymptomatic pulmonary recurrences were detected by chest radiographs. Pap smears did not detect a single asymptomatic recurrence. Conclusions. Posttherapy surveillance programs are directed toward asymptomatic patients in whom early detection of recurrence may impact survival. These data indicate that a subset of women may benefit from surveillance. A model for surveillance is proposed. (C) 2000 Academic Press.
UR - http://www.scopus.com/inward/record.url?scp=0033838518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033838518&partnerID=8YFLogxK
U2 - 10.1006/gyno.2000.5860
DO - 10.1006/gyno.2000.5860
M3 - Article
C2 - 10926801
AN - SCOPUS:0033838518
SN - 0090-8258
VL - 78
SP - 187
EP - 193
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 2
ER -